Hold. GSK trades at a reasonable 10.5× forward P/E with balanced risk-return: Value Compounder strength (65/100) supports the valuation floor, but Growth Compounder weakness (59/100) limits upside. Leadership Alignment at 70.3/100 is solid, though not exceptional. Primary vulnerability is financial-buffer-only protection—patent cliffs and pipeline execution remain key monitoring points. Suitable for income-focused holders; growth investors should wait for clearer organic acceleration.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for GSK plc:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 61/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates GSK plc (GSK) at 61/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. GSK trades at a reasonable 10.5× forward P/E with balanced risk-return: Value Compounder strength (65/100) supports the valuation floor, but Growth Compounder weakness (59/100) limits upside. Leadership Alignment at 70.3/100 is solid,
GSK's current Stocky Verdict is 61/100, placing it in the "Hold" band. This composite combines a 65/100 Compounder score, 70/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for GSK plc yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
GSK plc scores 70/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
GSK plc's Vulnerability Profile scores 50/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to GSK plc.
Sign up free and unlock the full analysis on GSK — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for GSK in the app.
